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L-type Ca2+ channels (LTCCs) play a crucial role in excitation-contraction coupling 
and the release of hormones from secretory cells. They are targets of numerous 
antihypertensive and antiarrhythmic drugs such as diltiazem. Here, we present a 
photoswitchable derivative of diltiazem, FHU-779, which can be used to reversibly 
block endogenous LTCCs by light. FHU-779 is almost as potent as diltiazem itself, 
and can be used to place pancreatic β cell function and cardiac activity under optical 
control.  
 
L-type Ca2+ channels (LTCCs, Cav1) serve fundamental physiological roles in 
excitable tissues1. Activated by membrane depolarization, LTCCs permit Ca2+ influx into 
cells and are key players in voltage-dependent signal transduction1,2. For instance, LTCCs 
are crucial for pacemaking, electrical conduction, and excitation-contraction coupling in 
the heart1. In pancreatic β cells, LTCCs are essential for excitation-secretion coupling 
affording insulin release3. To study the role of LTCCs in more detail, Ca2+ imaging 
techniques have been applied for monitoring the cytosolic Ca2+ concentration in living 
cells with high resolution4,5. However, tools to control Ca2+ influx through endogenous 
LTCCs with comparable temporal and spatial resolution have been lacking so far. We have 
addressed this experimental need by creating a photoswitch that enables control of LTCCs 
using light. 
 
Based on the structure of the benzothiazepine-like Ca2+ channel blocker diltiazem, we 
synthesized the doubly-charged, hydrophilic photoswitch FHU-779 by installing a 
photoresponsive azobenzene moiety (Fig. 1a,b; for synthesis see Supplementary Note). 
Under blue (470 nm) illumination or in the dark, the compound rests in its thermally more 
stable trans-state. Upon UV-A irradiation (385 nm), the compound is reversibly converted 
into its energetically elevated cis-state, which has a bent conformation. We characterized 
the spectral properties of cis- and trans-FHU-779 by UV-Vis spectroscopy (Fig. 1c). 
Thermal relaxation from cis- to trans-FHU-779 detected at 360 nm followed a mono-
exponential time course with a time constant of τ = 4081 ± 71 min (Supplementary Fig. 
1). To determine whether FHU-779 was able to afford optical control of LTCC function, 
we performed whole-cell patch clamp recordings using HEK293T cells heterologously 
expressing Cav1 channels. Current-voltage (I-V) relationships for Cav1.2 and Cav1.3 in the 
presence of cis- and trans-FHU-779 are shown in Fig. 1d and Supplementary Fig. 2, 
respectively (n = 3 cells each). In its trans-state, FHU-779 strongly reduced inward 
currents conducted by both channel subtypes. The block of Cav1 channels was reversible 
when FHU-779 was repeatedly photoswitched between its trans- and cis-states (Fig. 1e,f; 
Supplementary Fig. 2). Quantification of block induced by 25 µM externally applied FHU-
779 was impeded by LTCC current rundown6, yielding photoswitching efficacies of 46.5 ± 
7.6% and 46.4 ± 5.4% for Cav1.2 (n = 10 cells) and Cav1.3 channels (n = 9 cells), 
respectively (Fig. 1g). In contrast, FHU-779-mediated photoswitching of voltage-gated 
potassium (Kv) channels, which are reportedly blocked by high dose diltiazem7, was far 
less efficient with only 6.2 ± 2.7% (n = 6 cells) and 5.9 ± 3.0% (n = 6 cells) photoswitching 
detected for heterologously expressed Shaker-IR or Kv channels, respectively. Also, 
photoswitching quantification against voltage-gated sodium channel Nav1.5 by FHU-779 
showed only 5.4 ± 0.9% change (n = 10 cells). These data demonstrate that FHU-779 
endows light sensitivity to the two major LTCC subtypes, Cav1.2 and Cav1.3, but has 
negligible effects on Kv and Nav channels. In an attempt to determine the access route of 
FHU-779 into LTCCs, the drug was applied intracellularly via the patch pipette. Whole-cell 
dialysis of 100 µM FHU-779 resulted in negligible photoswitching of both Cav1.2 (8.6 ± 
6.0%; n = 4 cells) and Cav1.3 currents (2.0 ± 4.6%; n = 7 cells, Fig. 1g). This result suggests 
that FHU-779 enters LTCCs from the extracellular side rather than from the cytosol8.  
 
To more precisely quantify FHU-779 photoswitching, we loaded HEK293T cells 
heterologously expressing a Cav1.2 mutant deficient for channel inactivation 
(Cav1.2Δ1671)9 with the fluorescent Ca2+ indicator Fura-2 and performed ratiometric 
Ca2+ imaging10. LTCC channels were activated by membrane depolarization with high 
extracellular [K+], and the consecutive increase in intracellular Ca2+ ([Ca2+]i) was recorded 
(Fig. 2a; Supplementary Fig. 3; Supplementary Movies 1-3 and online methods). 
Subsequent wash-in of FHU-779 decreased cytosolic Ca2+ levels in the dark, whereas 
changing illumination wavelengths between 480 nm and 380 nm allowed for reliable 
optical control of Ca2+ influx into cells.  
 
The Ca2+ imaging based quantification of Cav1.2 block by diltiazem yielded a dose-
response relationship with an IC50 of 2.7 µM ± 1.0% (Supplementary Fig. 3), which is in 
accordance with the literature11,12 and in the same range as trans-FHU-779 showing an 
IC50 of 8.3 µM ± 0.6% (Fig. 2b). The difference between both dose-response relationships 
of trans-FHU-779 and cis-FHU-779 data represents quantitative photoswitching 
amplitudes at a given concentration.  
To rationalize these results, we constructed an open-state Cav1.2 model and docked FHU-
779 using a previously elaborated approach13 with the open NavAb channel X-ray 
structure as a template14 (Fig. 2c,d; Supplementary Fig. 4,5; Supplementary Table 1,2; 
online methods). The model accommodated trans-FHU-779 with the tricyclic moiety and 
the long chain as predicted for benziazem15, which shares a similar chemical structure as 
FHU-779. The benzothiazepine moiety was bound in the repeat III/IV fenestration, the 
protonated nitrogen resided near the selectivity filter, and the long photoswitchable 
moiety extended along the inner pore (Fig. 2c). cis-FHU-779 was also accommodated in 
the inner cavity, but the folded conformation was too bulky to access this site either 
through the open activation gate or a fenestration (Fig. 2d). 
To further explore the application spectrum of FHU-779 in primary cells and tissue 
endogenously expressing LTCCs, we used pancreatic islets and monitored [Ca2+]i in β cells 
by Fluo-8 fluorescence intensity imaging (Fig. 3a). When triggered by LTCC-mediated 
Ca2+ influx, pancreatic β cells secrete insulin to regulate blood glucose levels16. First, the 
sulfonylurea and ATP-sensitive K+ channel (KATP) blocker tolbutamide was applied to 
depolarize β cells and fully activate LTCCs17. This led to Ca2+ influx that was strongly 
reduced by trans-FHU-779 when cells were illuminated at 470 nm (Fig. 3a). This effect 
was reversed by illumination at 395 nm, yielding 52.2 ± 2.7% photoswitching (n = 9 islets, 
see online methods). Controls were performed relative to the magnitude of tolbutamide 
alone, and with diltiazem- and tolbutamide-treated islets (n = 9, Supplementary Fig. 6). 
Prior application of a saturating concentration of diltiazem precluded photoswitching by 
FHU-779 (Supplementary Fig. 6). Whole-cell patch clamp experiments in dissociated 
pancreatic β cells displayed reduced inward currents through LTCCs at 470 nm as 
compared to 370 nm light in the presence of FHU-779 (Fig. 3b), reinforcing our imaging 
results. In the absence of FHU-779, corresponding I-V relationships did not differ in 
current amplitude in response to illumination (Supplementary Fig. 6). Insulin secretion 
was determined in islets under control conditions (tolbutamide), or following application 
of diltiazem and cis- or trans-FHU-779 (Fig. 3c). As expected, only diltiazem and trans-
FHU-779 application were able to significantly reduce insulin secretion. To demonstrate 
the spatiotemporal control of LTCCs, we reversibly photoactivated FHU-779 in a single 
from a doublet or triplet islets of Langerhans (Supplementary Fig. 7), as well as in single 
beta cells residing within the intact microorgan (Fig. 3d-f), while performing Ca2+ imaging. 
As such, FHU-779 enables robust and precise spatiotemporal optical control of 
endogenous LTCC function, Ca2+ fluxes and insulin secretion in pancreatic β cells. 
 
FHU-779 was also applicable to explanted hearts perfused in the Langendorff 
configuration. Besides coupling excitation and contraction in cardiomyocytes, LTCCs are 
important for sinoatrial pacemaking in the right atrium and atrioventricular conduction1. 
FHU-779 was perfused into coronary arteries and the right atrium was illuminated. In line 
with the LTCC-block by trans-FHU-779, illumination with 480 nm reduced heart rate, 
which was quickly reversed by 380 nm illumination (Fig. 3g). Photoswitching 
significantly affected the heart rate by 5.8 ± 1.8% (n = 4 hearts) in comparison to control 
experiments, which were performed prior to FHU-779 application but with the same 
illumination protocol (Fig. 3h). We also screened for the optimal irradiation wavelength, 
and found that 360 nm illumination achieved the largest increase in heart rate while 400 
nm light was still effective (Supplementary Fig. 8). Furthermore, we analyzed the 
relationship between cycle length for switching between 480 nm and 380 nm illumination 
and heart rate response and found a maximal effect at 30 s of illumination 
(Supplementary Fig. 8). These experiments were further substantiated by whole-cell 
patch-clamp recordings of LTCC currents from adult cardiomyocytes and revealed 
photoswitching of 20.5 ± 8.8% (n = 12 cells) (Supplementary Fig. 8). To demonstrate 
spatial control of cardiomyocyte function, Cor4U cardiomyocytes were plated on 
microelectrode arrays (MEA) and treated with FHU-779. The duration of extracellular 
field potentials (FPs), which is reflecting the LTCC-dependent plateau phase of the cardiac 
action potential18 was measured from individual electrodes, and only part of the MEA was 
illuminated with either 385 nm or 480 nm light. The illuminated electrodes showed a FP 
prolongation upon UV-light and FP shortening using 480 nm indicating activation and 
block of LTCCs, respectively (Fig. 3i). This effect could be changed repetitively and was 
not observed on non-illuminated electrodes of the same MEA (Supplementary Fig. 9). 
  
In conclusion, we present a tool to reversibly control one of the main gates of Ca2+ influx 
into excitable cells, the LTCCs, at spatiotemporal precision of light. Derived from the 
clinically used LTCC blocker diltiazem, our molecule is applicable in dissociated primary 
cells and ex vivo organ preparations. In contrast to genetically encoded optogenetic tools, 
such as ChR219, OptoSTIM120, or Opto-CRACK20, FHU-779 bestows light sensitivity to 
endogenous LTCCs. Compared to light-flash photolysis of nifedipine for optical control of 
LTCC activity21,22, FHU-799 extends experimental options by adding a high temporal 
reversibility. Thus, biological processes involving LTCC-related Ca2+oscillations may now 
be accessed; also, localized modulation of LTCC-induced cardiac arrhythmia can be 
envisaged. Since FHU-779 serves as new lead structure, further chemical modifications 
will multiply specific LTCC tools and thus biological applications.  
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Supplementary Table 1. Sequence alignment and benzothiazepine-sensing residues  
 
Channel Segment # a Sequence b,c 
             p40            p50 
          |              |       
NavAb 
Cav1.2 
P 
IP 
IIP 
IIIP 
IVP 
1159 
375 
719 
1128 
1429 
WFGLGESF YTLFQVMTLE SWSMGIV 
FDNFAFAM LTVFQCITME GWTDVLY 
FDNFPQSL LTVFQILTGE DWNSVMY 
FDNVLAAM MALFTVSTFE GWPELLY 
FQTFPQAV LLLFRCATGE AWQDIML 
 
              i10            i20            i30 
           |              |              |  
NavAb 
Cav1.2 
 
 
 
S6 
IS6 
IIS6 
IIIS6 
IVS6 
1193 
410 
758 
1171 
1481 
YAWVFFIPF IFVVFFVMIN LYVAIIVDAMAI  
LPWVYFVSL VIFGSFFVLN LVLGVLSGEFSK  
LVCIYFIIL FICGNYILLN VFLAIAVDNLAD 
EISIFFIIY IIIIAFFMMN IFVGFVIVTFQE 
FAVFYFISF YMLCAFLIIN LFVAVIMDNFDY  
 
a Residue numbers in the Cav1.2 channel are given according UniProtKB - P15381 (CCAC_RABIT) and 
in the NavAb channel according to X-ray structures (PDB codes 5VB8, 5VB2).  
b Labels, which are universal for P-loop channels 1, are shown above respec!ve sequences. 
c Experimentally determined benzothiazepine-sensing residues 2-4 are bold-typed  and underlined.   
Supplementary Table 2. Interacon energy of trans- and cis-FHU-779 with the Cav1.2 model 
paroned by the channel residues a 
 
P-loops  Energy, kcal/mol S6 
i11-i22 
Energy, kcal/mol S6 
i23-i30 
Energy, kcal/mol 
trans-  cis-  trans-  cis-  trans-  cis-  
F1139(3p44) -0.70 -2.98 I1179(3i11) -1.11 -1.16 L778(2i23) -0.58  
S1142(3p47) -1.97 -1.17 Y1489(4i11) -3.48 -2.20 L1191(3i23) -0.9  
A1443(4p47) -0.68 -2.39       
T1143(3p48) -2.37 -0.73 I1180(3i12)   -0.53 L433(1i26) -3.05  
T1444(4p48) -3.11 -2.72 M1490(4i12) -1.19 -1.19 A781(2i26) -1.28  
M391(1p49) -1.03 -0.75    V1194(3i26) -1.08  
F1144(3p49) -2.22 -2.57 I1182(3i14) -1.12 -0.88 I1504(4i26) -1.16  
E1145(3p50) -0.90 -0.70       
E1446(4p50) -0.73 -0.67 A1493(4i15) -3.13 -1.75 F437(1i30) -1.62  
      L785(2i30) -1.13  
   F1494(4i16) -0.80  F1198(3i30) -1.45  
      F1508(4i30) -1.52  
   F1185(3i17) -0.52 -0.72    
         
   V425(1i18)  -0.75    
   L773(2i18)  -2.21    
   M1186(3i18) -2.22 -3.87    
   I1496(4i18) -0.93     
         
   L426(1i19) -1.21 -1.77    
   L774(2i19)  -1.28    
   M1187(3i19) -0.80     
   I1497(4i19) -1.44     
         
   V429(1i22) -2.04 -1.13    
   F777(2i22) -0.61 -6.40    
   F1190(3i22) -3.65 -3.26    
   F1500(4i22) -3.55 -2.68    
         
Total  -14.91 -18.26 Total -28.55 -35.14 Total -15.90 0.00 
         
trans-FHU-779 Total   -58.73              cis-FHU-779 Total   -53.40 
         
 
Residues are designated by their genuine numbers in the rabbit Cav1.2 channel and bracketed universal 
labels (see Supplementary Table 1). Residues, for which the absolute value of their energy 
contribution to the ligand-channel interacon energy is less than 0.5 kcal/mol are not shown, but their 
energy contribuons are included in the total energies.  Residues whose mutaons are known to aﬀect 
action of benzothiazepines (Supplementary Table 1) are underlined. 
 
 
Figure 1 | Design and characterization of the light-regulated diltiazem derivative 
FHU-779.  
(a,b) Chemical structures of (a) diltiazem and (b) its photoswitchable derivative FHU-
779. Thermally stable trans-FHU-779 can be isomerized to its cis-state using 385 nm 
irradiation, while 470 nm irradiation or thermal relaxation (kBT) reverses the process. (c) 
The UV-Vis absorption spectra of FHU-779 under continuous irradiation at 380 nm, 480 
nm or without additional illumination (dark). (d-g) Whole-cell patch clamp recordings of 
Cav1.2 Ba2+ currents in the presence of FHU-779 (25 μM) under 385 nm or 470 nm 
irradiation. Cav1.2 channels were heterologously expressed in HEK293T cells together 
with the β3 and α2δ1 auxiliary subunits. (d) I-V relationship of peak currents under 385 
nm or 470 nm illumination. Voltage dependent currents were elicited by stepping from –
70 mV to +80 mV in 10 mV increments at 1 Hz for 100 ms. Indicated color code applies 
also for (e) and (f). (e) A representative single current trace demonstrates reversible 
light-dependent block of Cav1.2 by FHU-779 (25 µM). Displayed are the last triggered 
current-responses of 16 depolarizations under 385 nm and 470 nm irradiation, 
respectively. Currents were triggered by stepping from a holding potential of −70 mV to 
+30 mV at 1 Hz for 100 ms. Parallel lines represent time gap between currents. (f) Peak 
Cav1.2 Ba+ currents under 385 nm and 470 nm irradiation over multiple cycles. (g) 
Quantification of photoswitching induced by extracellularly or internally applied FHU-
779 (25 μM and 100 µM, respectively). Statistical evaluation by one way ANOVA test, *p < 
0.05, **p < 0.01, ***p < 0.001 (definition of photoswitching see online methods).  
 
 
Figure 2 | FHU-779 enables optical control of LTCC conductance. (a,b) Ratiometric 
Ca2+ imaging of Fura-2- loaded HEK293T cells expressing Cav1.2Δ1671, β3, α2δ1 and 
TRAAK-GFP constructs in the presence of FHU-779. Cells were depolarized by K+ (60 mM) 
to activate LTCCs. (a) Representative Ca2+ signals in a single transfected HEK293T cell 
under alternating 380 nm and 480 nm illumination (40 μM FHU-779). (b) Dose-response 
relationships of trans- and cis-FHU-779 determined by ratiometric Ca2+ imaging (see 
Supplementary Fig. 3 and online methods). (c,d) The pore domain-model of the open L-
type calcium channel with compound FHU-779 bound in the trans- (c) and cis- (d) 
conformations. The channel repeats I, II and IV are colored by yellow, magenta and cyan, 
respectively. For clarity, repeat III is not shown. 
 
Figure 3 | FHU-779 allows photoswitching of LTCC in pancreatic β cells, 
cardiomyocytes and mouse hearts. (a) Reversible optical control of cytosolic Ca2+ levels 
measured by intensity-based Ca2+ imaging in mouse pancreatic islets using FHU-779 (35 
µM). Representative Ca2+ signals from four islets (grey) imaged simultaneously (F/Fmin 
represents fluorescence/minimal fluorescence in respective trace). The black line 
represents the mean. (b) Whole-cell patch clamp experiments in dissociated β cells. 
Displayed as the I-V relationship in the presence of FHU-779 (35 μM, n = 7 cells from 3 
animals) under 370 nm and 470 nm irradiation. In all experiments, tolbutamide (200 µM) 
was added to block KATP channels and maintain LTCCs in the open state. (c) Insulin 
secretion under control conditions (11 mM glucose + 200 µM tolbutamide) and following 
application of either diltiazem (50 µM), trans-FHU-779 or cis-FHU-779 (35 µM) (n = 4 
animals, circles represent individual data points). Statistical evaluation by one way 
ANOVA followed by Dunnett’s multiple comparison test, *p < 0.05, **p < 0.01. (d-f) Ca2+ 
imaging of FHU-779 block release in single β cells residing within intact pancreatic islets. 
(d) Representative image before and during targeted irradiation of ROI (1) with 405 nm 
light (photoactivated ROI, white solid line (1); control ROI, grey solid line (2); scale bar = 
50 μm; representative images, n = 7 islets from 3 animals). (e) Close up of photoactivated 
ROI (1) before and during 405 nm irradiation (colored map applies to d and e, W/O 
represents without). (f) Time course of F/Fmin, before and during block release of 
representative ROIs (1 and 2) (n = 7 islets from 3 animals). (g,h) Heart rate modulation 
by FHU-779 (25 μM) in intact mouse hearts. (g) In the presence of FHU-779, 480 nm 
illumination of the right atrium decreased the spontaneous beating rate of a 
representative single heart. 380 nm reversed this effect. (h) Quantification of heart rate 
change induced by 380 nm light relative to 480 nm illumination before FHU-779 (W/O) 
and in the presence of FHU-779 (n = 4 hearts, two tailed, paired student t-test, *p = 
0.0375). (i) Overlay of representative field potential (FP) signals of a monolayer Cor4U 
cardiomyocytes incubated with FHU-779 (10 µM). One electrode was in the illuminated 
region (i) of the MEA and the second electrode was in the non-illuminated area 
(Supplementary Fig. 9). The FP duration in (i) was determined to be 170.4 ± 14.8, 186.3 
± 15.9 ms for 480 nm and 385 nm, respectively (n = 4, paired t-test *p = 0.0159). 
 
 
